27680598|t|Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth
27680598|a|Sarcoma accounts for 20% of solid tumors in children. Surgery has significant morbidity. We hypothesized that delivering chemotherapy directly into tumors through sustained release silk systems could slow tumor growth. Human Ewing sarcoma cells A673 were cultured with vincristine and doxorubicin to determine half maximal inhibitory concentration (IC50). Cells were injected into mouse hind leg to create orthotopic tumors. Tumor volumes were measured using ultrasound. When volume reached >250mm(3,) interventions included: implantation of drug-free silk foam (Control -F), doxorubicin 400μg foam (Dox400 -F), vincristine 50μg foam (Vin50 -F), drug-free silk gel (Control -G), vincristine 50μg gel (Vin50 -G), or single dose intravenous vincristine 50μg (Vin50 -IV). End-point was volume>1000mm(3). Kaplan Meier and ANOVA were used. IC50 for vincristine and doxorubicin was 0.5ng/mL and 200ng/mL, respectively. There was no difference between Dox400 -F [6± 1days to end point (DTEP)] and Control -F (5±1.3 DTEP). Vin50 -F (12.4±3.5 DTEP) had slower growth compared to Control -F (p<0.001), and there was no difference between Vin50 -F and Vin50 -IV (14±0 DTEP). Growth was slowest with Vin50 -G, 28±10.3 DTEP compared to all other treatment groups (p<0.05). Sustained delivery of vincristine inside the sarcoma tumor with silk gel decreased tumor growth. Applying this intratumoral treatment strategy may potentially decrease the extent of surgical excision.
27680598	0	18	Sustained delivery	T103	UMLS:C1710261
27680598	22	33	vincristine	T103	UMLS:C0042679
27680598	44	54	orthotopic	T082	UMLS:C0574893
27680598	55	68	mouse sarcoma	T038	UMLS:C1522023
27680598	98	105	Sarcoma	T038	UMLS:C1261473
27680598	126	138	solid tumors	T038	UMLS:C0280100
27680598	152	159	Surgery	T058	UMLS:C0543467
27680598	219	231	chemotherapy	T058	UMLS:C3665472
27680598	246	252	tumors	T038	UMLS:C0027651
27680598	261	278	sustained release	T103	UMLS:C1710261
27680598	279	283	silk	T103	UMLS:C0074529
27680598	317	322	Human	T204	UMLS:C0086418
27680598	323	336	Ewing sarcoma	T038	UMLS:C0553580
27680598	337	347	cells A673	T017	UMLS:C0334227
27680598	353	361	cultured	T058	UMLS:C0430400
27680598	367	378	vincristine	T103	UMLS:C0042679
27680598	383	394	doxorubicin	T103	UMLS:C0013089
27680598	454	459	Cells	T017	UMLS:C0334227
27680598	479	484	mouse	T204	UMLS:C0025929
27680598	485	493	hind leg	T017	UMLS:C1522391
27680598	504	514	orthotopic	T082	UMLS:C0574893
27680598	515	521	tumors	T038	UMLS:C0027651
27680598	557	567	ultrasound	T058	UMLS:C0041618
27680598	600	613	interventions	T058	UMLS:C0184661
27680598	624	636	implantation	T058	UMLS:C0021107
27680598	650	654	silk	T103	UMLS:C0074529
27680598	674	685	doxorubicin	T103	UMLS:C0013089
27680598	697	704	(Dox400	T103	UMLS:C0013089
27680598	710	721	vincristine	T103	UMLS:C0042679
27680598	733	738	Vin50	T103	UMLS:C0042679
27680598	754	758	silk	T103	UMLS:C0074529
27680598	777	788	vincristine	T103	UMLS:C0042679
27680598	799	804	Vin50	T103	UMLS:C0042679
27680598	825	836	intravenous	T082	UMLS:C0348016
27680598	837	848	vincristine	T103	UMLS:C0042679
27680598	855	860	Vin50	T103	UMLS:C0042679
27680598	942	953	vincristine	T103	UMLS:C0042679
27680598	958	969	doxorubicin	T103	UMLS:C0013089
27680598	1043	1049	Dox400	T103	UMLS:C0013089
27680598	1113	1118	Vin50	T103	UMLS:C0042679
27680598	1142	1155	slower growth	T033	UMLS:C4086857
27680598	1226	1231	Vin50	T103	UMLS:C0042679
27680598	1239	1244	Vin50	T103	UMLS:C0042679
27680598	1262	1280	Growth was slowest	T033	UMLS:C4086857
27680598	1286	1291	Vin50	T103	UMLS:C0042679
27680598	1358	1376	Sustained delivery	T103	UMLS:C1710261
27680598	1380	1391	vincristine	T103	UMLS:C0042679
27680598	1403	1410	sarcoma	T038	UMLS:C1261473
27680598	1411	1416	tumor	T038	UMLS:C0027651
27680598	1422	1426	silk	T103	UMLS:C0074529
27680598	1469	1491	intratumoral treatment	T058	UMLS:C1831733
27680598	1540	1557	surgical excision	T058	UMLS:C0728940